4-Antibody AG Announces New Board Appointment
4-Antibody AG announced the appointment of Dr Thomas von Rüden to its Board of Directors.
Dr von Rüden was formerly CEO at DIREVO Industrial Biotechnology GmbH, Cologne, Germany. Before this, he was the Chairman of DIREVO’S Advisory Board and worked as President and Chief Executive Officer at DIREVO Biotech AG until the company was acquired by Bayer Schering in September 2008. Prior to joining DIREVO in 2006, he spent six years as the CSO and Executive VP of Business Development with MorphoSys AG in Munich. Before that he was Director of Molecular Biology responsible for drug discovery in oncology at Boehringer Ingelheim in Vienna after holding academic positions at the European Laboratory of Molecular Biology, Heidelberg, and the Institute of Molecular Pathology, Vienna. He holds several advisory board positions in biotechnology companies and public research organizations.
Other news from the department people
